Results and challenges of immune checkpoint inhibitors in colorectal cancer

References

• Fact Sheets by Cancer [Internet]. cited 2017 Jun 9. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422.
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: A randomized clinical trial. Jama. 2017;317:2392–2401.
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Cremolini C, Sartore-Bianchi A, et al. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget. 2015;6:31604–31612.
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Köhne C-H, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–2019.
   PubMed Web of Science ®Google Scholar
• Bever KM, Le DT. An expanding role for immunotherapy in colorectal cancer. J Natl Compr Cancer Netw. 2017;15:401–410.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.
   PubMed Web of Science ®Google Scholar
• Boland PM, Ma WW. Immunotherapy for colorectal cancer. Cancers. 2017;11:9.
   Google Scholar
• Tougeron D, Mouillet G, Trouilloud I, et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: A large multicenter AGEO study. J Natl Cancer Inst. 2016;108(7).
   PubMedGoogle Scholar
• Dudley JC, Lin M-T, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813–820.
   PubMed Web of Science ®Google Scholar
• Funkhouser WK, Lubin IM, Monzon FA, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn. 2012;14:91–103.
   PubMed Web of Science ®Google Scholar
• Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet. 2009;41:112–117.
   PubMed Web of Science ®Google Scholar
• Kim H, Jen J, Vogelstein B, et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994;145:148–156.
   PubMed Web of Science ®Google Scholar
• Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–2100.
   PubMed Web of Science ®Google Scholar
• Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268.
   PubMed Web of Science ®Google Scholar
• Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5257.
   PubMed Web of Science ®Google Scholar
• Colle R, Cohen R, Cochereau D, et al. Immunotherapy and patients treated for cancer with microsatellite instability. Bull Cancer. 2017;104:42–51.
   PubMed Web of Science ®Google Scholar
• Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126:394–401.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–3226.
   PubMed Web of Science ®Google Scholar
• Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322–5330.
   PubMed Web of Science ®Google Scholar
• Tougeron D, Sueur B, Sefrioui D, et al. A large multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancers with microsatellite instability. J Clin Oncol. 2017;35(15_suppl):abstr 3536.
   Google Scholar
• Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol. 2015;6:208–223.
   PubMed Web of Science ®Google Scholar
• Boissière-Michot F, Lazennec G, Frugier H, et al. Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology. 2014;3:e29256.
   PubMed Web of Science ®Google Scholar
• Gou H-F, Huang J, Shi H-S, et al. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PloS One. 2014;9:e85789.
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47–64.
   PubMed Web of Science ®Google Scholar
• Zamai L, Ponti C, Mirandola P, et al. NK cells and cancer. J Immunol. 2007;178:4011–4016.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–2666.
   PubMed Web of Science ®Google Scholar
• Laghi L, Bianchi P, Miranda E, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 2009;10:877–884.
   PubMed Web of Science ®Google Scholar
• Koch M, Beckhove P, Op den Winkel J, et al. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244:986–992.
   PubMed Web of Science ®Google Scholar
• Keogh E, Fikes J, Southwood S, et al. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol Baltim. 2001;167:787–796.
   PubMed Web of Science ®Google Scholar
• Tougeron D, Fauquembergue E, Rouquette A, et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol. 2009;22:1186–1195.
   PubMed Web of Science ®Google Scholar
• Saeterdal I, Gjertsen MK, Straten P, et al. A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. Cancer Immunol Immunother. 2001;50:469–476.
   PubMed Web of Science ®Google Scholar
• Browning M, Petronzelli F, Bicknell D, et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens. 1996;47:364–371.
   PubMed Web of Science ®Google Scholar
• Tirapu I, Huarte E, Guiducci C, et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res. 2006;66:2442–2450.
   PubMed Web of Science ®Google Scholar
• Haas M, Dimmler A, Hohenberger W, et al. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol. 2009;9:65.
   PubMed Web of Science ®Google Scholar
• Tougeron D, Fauquembergue E, Latouche JB. Immune response and colorectal cancer. Bull Cancer. 2013;100:283–294.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol. 2017;18:843–850.
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800–812.
   PubMed Web of Science ®Google Scholar
• Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488–492.
   PubMed Web of Science ®Google Scholar
• Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. Jama. 2004;291:187–194.
   PubMed Web of Science ®Google Scholar
• Coley WB. Treatment of inoperable malignant tumors with the toxins of erysipelas and the Bacillus prodigiosus. Trans Amer SurgAssn. 1894;12:183–212.
   Google Scholar
• Sobhani I, Amiot A, Le Baleur Y, et al. Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? TherapAdvGastroenterol. 2013;6(3):215–229.
   Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482–491.
   PubMed Web of Science ®Google Scholar
• Limagne E, Euvrard R, Thibaudin M, et al. Accumulation of MDSC and Th17 Cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-Bevacizumab drug treatment regimen. Cancer Res. 2016;76:5241–5252.
   PubMed Web of Science ®Google Scholar
• Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3:610–619.
   PubMed Web of Science ®Google Scholar
• Demaria S, Formenti SC. Radiotherapy effects on anti-tumor immunity: implications for cancer treatment. Front Oncol. 2013;3:128.
   PubMedGoogle Scholar
• Seyedin SN, Schoenhals JE, Lee DA, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015;7:967–980.
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR, Liang H, Deng L. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14:365–379.
   PubMed Web of Science ®Google Scholar
• De Guillebon E, Roussille P, Frouin E, et al. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol. 2015;7:95–101.
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;12:1245–1252.
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–1191.
   PubMed Web of Science ®Google Scholar
• Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010;28:3485–3490.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413.
   PubMed Web of Science ®Google Scholar
• Andre T, Lonardi S, Wong KYM, et al. Combination of nivolumab + ipilimumab in the treatment of patients with deficient DNA mismatch repair high microsatellite instability metastatic colorectal cancer: checkMate 142 study. J Clin Oncol. 2017;15:suppl;abstr 3531.
   Google Scholar
• Pagès F, Galon J, Dieu-Nosjean M-C, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–1102.
   PubMed Web of Science ®Google Scholar
• Camus M, Tosolini M, Mlecnik B, et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009;69:2685–2693.
   PubMed Web of Science ®Google Scholar
• Galon J, Pagès F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610–618.
   PubMed Web of Science ®Google Scholar
• Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205.
   PubMed Web of Science ®Google Scholar
• M-G A, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20:1891–1899.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Van Den Eynde M, Bindea G, et al. Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst. 2018;110:97-108.
   Google Scholar
• Emile J-F, Julié C, Le Malicot K, et al. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. Eur J Cancer. 2017;82:16–24.
   PubMed Web of Science ®Google Scholar
• Sinicrope F, Shi Q, Hermitte F, et al. Association of immune markers and Immunoscore with survival of stage III colon carcinoma patients treated with adjuvant FOLFOX: NCCTG N0147 (Alliance). J Clin Oncol. 2017;15:suppl:abstr3579.
   Google Scholar
• Allard MA, Bachet JB, Beauchet A, et al. Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. Diagn Pathol. 2012;7:156.
   PubMed Web of Science ®Google Scholar
• Tanis E, Julié C, Emile J-F, et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. Eur J Cancer. 2015;51:2708–2717.
   PubMed Web of Science ®Google Scholar
• Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PloS One. 2015;10:e0130142.
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23:2965–2970.
   PubMed Web of Science ®Google Scholar
• Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer. 2013;49:2233–2242.
   PubMed Web of Science ®Google Scholar
• André T, Overman M, Lonardi S, et al. 484PD Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients with deficient DNA mismatch repair high microsatellite instability metastatic colorectal cancer treated with nivolumab + ipilimumab: checkMate 142. Ann Oncol [Internet]. 2017;28. cited 2017 Oct 12.
   Web of Science ®Google Scholar
• Zhao J, Zhang P, Wang J, et al. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Medicine (Baltimore). 2017;96:e6102.
   PubMed Web of Science ®Google Scholar
• Sheng J, Fang W, Yu J, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090.
   PubMed Web of Science ®Google Scholar
• Tietze JK, Angelova D, Heppt MV, et al. The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. Eur J Cancer. 2017;75:268–279.
   PubMed Web of Science ®Google Scholar
• Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148:77–87.e2.
   PubMed Web of Science ®Google Scholar
• French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008;14:3408–3415.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–1356.
   PubMed Web of Science ®Google Scholar
• Stadler ZK, Battaglin F, Middha S, et al. Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in Next-Generation Sequencing panels. J Clin Oncol. 2016;34:2141–2147.
   PubMed Web of Science ®Google Scholar
• Gong J, Wang C, Lee PP, et al. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J Natl Compr Canc Netw. 2017;15:142–147.
   PubMed Web of Science ®Google Scholar
• Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;S2211–1247
   Google Scholar
• Becht E, De Reyniès A, Giraldo NA, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016;22:4057–4066.
   PubMed Web of Science ®Google Scholar
• Ngeow J, Eng C. Mismatch repair deficiency in colorectal cancers: is somatic genomic testing the grab-bag for all answers? J. Clin Oncol. 2016;34:2085–2087.
   Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Powderly JD, Lieu CH, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab and/or FOLFOX in patients with metastatic colorectal cancer. J Clin Oncol. 2015;33(suppl):abstr704.
   Google Scholar
• Bendell JC, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib and atezolizumab in colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr3502.
   Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–695.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–931.
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Chen DS, Knox SJ. Abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:2035.
   PubMed Web of Science ®Google Scholar
• Segal NH, Kemeny NE, Cercek A, et al. Non-randomized phase II study to assess the efficacy of pembrolizumab plus radiotherapy or ablation in mismatch repair proficient metastatic colorectal cancer patients. J Clin Oncol. 2016;34(suppl):abstr3539.
   Google Scholar
• Marzbani E, Inatsuka C, Lu H, et al. The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res. 2013;8:764–773.
   Google Scholar
• von knebel Doeberitz M, Kloor M. Towards a vaccine to prevent cancer in Lynch syndrome patients. Familial Cancer. 2013;2:307–312.
   Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845–1855.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–e152.
   PubMed Web of Science ®Google Scholar
• Tanvetyanon T, Gray JE, Antonia SJ. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Expert Opin. Biol Ther. 2017;17:305–312.
   Google Scholar